Table 2.
Incidence of AEs, serious AEs, and CDC category C events.
| Patients, n (%) | MVC 300 mg b.i.d. (n = 360) | EFV 600 mg q.d. (n = 361) |
| All causality | ||
| AEs | 343 (95.3) | 347 (96.1) |
| Serious AEs | 77 (21.4) | 82 (22.7) |
| Grade 3 AEsa | 99 (27.5) | 106 (29.4) |
| Grade 4 AEsa | 44 (12.2) | 45 (12.5) |
| Discontinuations due to AEs | 38 (10.6) | 77 (21.3) |
| Treatment-related | ||
| AEs | 248 (68.9) | 295 (81.7) |
| Serious AEs | 12 (3.3) | 16 (4.4) |
| Discontinuations due to AEs | 19 (5.3) | 51 (14.1) |
| Dose reduced or temporary discontinuation due to AEs | 6 (1.7) | 9 (2.5) |
| Patients with CDC category C events | 11 (3.1) | 14 (3.9) |
| Infections and infestations | 9 (2.5) | 9 (2.5) |
| Neoplasms | 2 (0.6) | 5 (1.4) |
AE, adverse event; b.i.d., twice daily; CDC, Center for Disease Control; EFV, efavirenz; MVC, maraviroc; q.d., once daily.
aFor Grade 3/ 4 AEs; if the same patient in a given treatment had more than one occurrence in the same preferred term event category, only the most severe (grade 4) occurrence was taken. If the same patient had two different preferred term events, one classified as grade 3 and one as grade 4, they were presented in both rows.